CRISPR Therapeutics (NASDAQ: CRSP) specializes in gene editing, or the repair of faulty genes responsible for disease. Right now, CRISPR is heading for its biggest moment ever -- a regulatory decision on what may become its first commercialized product. The U.S. Food and Drug Administration (FDA) is set to decide on exa-cel for sickle cell disease in December and on exa-cel for beta thalassemia in March.
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
In the latest trading session, Moderna (MRNA) closed at $100.27, marking a +0.83% move from the previous day.